Furthermore, ADD3 has been associated with temozolomide (TMZ) resistance (Poon et al, 2015), glioma progression (Rani et al, 2013; van den Boom et al, 2003), and reduced glioma cell motility (Mariani et al, 2001). Here, ADD3 is linked to glioma.